Cooley LLP announced that it advised Insys Therapeutics on its initial public offering. Insys Therapeutics, now trading on the NASDAQ Stock Market under the symbol “INSY,” is an Arizona-based commercial-stage specialty pharmaceutical company. Insys develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products.

The Cooley corporate securities team advising Insys Therapeutics included partners Charlie Kim, Matthew Browne and Sean Clayton, and associates Asa Henin, Kevin Henderson, Brandon Batt and Terren O’Connor. Regulatory expertise was provided by partners Natasha Leskovsek and Drew Gantt and associate David Sclar. Partner Amy Wood and associate Megan Arthur provided compensation and benefits expertise and partner Susan Cooper Philpot provided tax expertise.


Related Posts:

Leave a Reply